Showing results (301-310 of 323) with videos related to
Sort By:
Pageof 33
Molecular Oncology|May 27, 2022
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancersMonica Niger, Federico Nichetti, Andrea Casadei-Gardini, et al.Journal of Cancer Policy|January 14, 2026
Defining the Role and Competencies of the Medical Oncologist in Diagnostic and Therapeutic Care Pathways: Consensus Recommendations from the Italian Association of Medical Oncology (AIOM)Rossana Berardi, Francesca Rossi, Valentina Tarantino, et al.Journal for Immunotherapy of Cancer|February 10, 2025
Sex and outcomes of patients with microsatellite instability-high and <i>BRAF</i> V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitorsVincenzo Nasca, Joseph Zhao, Javier Ros, et al.European Urology|May 8, 2020
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma PatientsLisa Derosa, Bertrand Routy, Marine Fidelle, et al.The Lancet. Oncology|March 14, 2020
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Carlotta Antoniotti, Daniele Rossini, et al.The British Journal of Surgery|July 25, 2024
Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective studyGeorgios Antonios Margonis, Jaeyun Jane Wang, Thomas Boerner, et al.Annals of Surgery|December 1, 2022
Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical QuestionsGeorgios A Margonis, Thomas Boerner, Jean-Baptiste Bachet, et al.BMC Cancer|April 8, 2024
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY studyMonica Niger, Federico Nichetti, Lorenzo Fornaro, et al.European Journal of Cancer (Oxford, England : 1990)|July 16, 2025
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM studyDavide Ciardiello, Luca Boscolo Bielo, Stefania Napolitano, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 29, 2025
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON StudyCarolina Sciortino, Federico Nichetti, Francesca Bergamo, et al.Pageof 33